Our research leverages an advanced murine skin infection model to drive the development and evaluation of innovative therapeutics addressing the global challenge of antimicrobial resistance. This platform enables us to explore novel approaches, particularly targeting bacterial biofilms, which play a critical role in persistent infections. By unraveling bacterial infection strategies, we aim to develop transformative solutions that redefine treatment paradigms in healthcare.

A key focus of our work is the design of antibiotic-conjugates—engineered formulations that enhance the cellular uptake and efficacy of existing drugs. This approach represents a promising strategy to outmaneuver bacterial resistance mechanisms, offering new avenues to combat antibiotic-resistant pathogens. Our research is poised to contribute to the next generation of antimicrobial innovations, paving the way for improved outcomes in the fight against resistant infections.